1

2

3
Michael R Myers, Alfred P Spada, Paul E Persons, Martin P Maguire: Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases. Avantis Pharmaceuticals, Peter J Butch, Raymond S Parker III, February 25, 2003: US06524347 (181 worldwide citation)

This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to diso ...


4
Alfred P Spada, Michael R Myers, Martin P Maguire, Paul E Persons: Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase. Rhone Poulenc Rorer Pharmaceuticals, James A Nicholson, Martin F Savitzky, Raymond S Parker III, January 2, 1996: US05480883 (166 worldwide citation)

This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferatio ...


5
Michael R Myers, Alfred P Spada, Martin P Maguire, Paul E Persons: Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase. Rhone Poulenc Rorer Pharmaceuticals, Raymond S Parker III, James A Nicholson, Martin F Savitzky, January 20, 1998: US05710158 (144 worldwide citation)

This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compou ...


6
Alfred P Spada, Martin P Maquire, Paul E Persons, Michael R Myers: Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase. Rhone Poulenc Rorer Pharmaceuticals, James A Nicholsen, Martin F Savitzky, Raymond S Parker III, April 25, 1995: US05409930 (127 worldwide citation)

This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferatio ...


7
Michael R Myers, Alfred P Spada, Martin P Maguire, Paul E Persons: Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties. Rhone Poulenc Rorer Pharmaceuticals, Raymond S Parker III, James A Nicholson, Martin F Savitzky, February 24, 1998: US05721237 (110 worldwide citation)

This invention relates to a method for the selective treatment of cell growth and differentiation characterized by activity of the human epidermal growth factor receptor type 2 (HER2). More specifically, this invention relates to the use of substituted or unsubstituted mono- or bi-cyclic aryl, heter ...


8
Alfred P Spada, Michael R Myers, Martin P Maguire, Paul E Persons: Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase. Rhone Poulenc Rorer Pharmaceuticals, Raymond S Parker III, James A Nicholson, Martin F Savitzky, July 8, 1997: US05646153 (106 worldwide citation)

This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferatio ...


9
Michael R Myers, Alfred P Spada, Martin P Maguire, Paul E Persons, Asher Zilberstein, Chin Yi Jenny Hsu, Susan E Johnson: Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase. Rhone Poulenc Rorer Pharmaceuticals, Raymond S Parker III, James A Nicholson, Martin F Savitzky, February 3, 1998: US05714493 (79 worldwide citation)

This invention relates to the treatment of intimation in a patient suffering from such disorder. More specifically, the invention relates to mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in the treatment of inflammation.


10
Michael L Edwards, Paul J Cox, Shelley Amendola, Stephanie D Deprets, Timothy A Gillespy, Christopher D Edlin, Andrew D Morley, Charles J Gardner, Brian Pedgrift, Herve Bouchard, Didier Babin, Laurence Gauzy, Alain Le Brun, Tahir N Majid, John C Reader, Lloyd J Payne, Nawaz M Khan, Michael Cherry: Benzimidazoles. Aventis Pharmaceuticals, Paul Darkes, George Wang, Raymond S Parker III, May 24, 2005: US06897208 (69 worldwide citation)

The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula ...